Therapeutic Potential of Cannabinoids in Psychosis

@article{Leweke2016TherapeuticPO,
  title={Therapeutic Potential of Cannabinoids in Psychosis},
  author={F. Leweke and J. K. Mueller and B. Lange and C. Rohleder},
  journal={Biological Psychiatry},
  year={2016},
  volume={79},
  pages={604-612}
}
  • F. Leweke, J. K. Mueller, +1 author C. Rohleder
  • Published 2016
  • Psychology, Medicine
  • Biological Psychiatry
  • Over recent years, the interest in the endocannabinoid system (ECS) as a new target for the treatment of schizophrenia has evolved. The ECS represents one of the most relevant neurotransmitter systems in the brain and mainly fulfills a homeostatic role in terms of neurotransmission but also with respect to inflammatory processes. Two main approaches to the modulation of endocannabinoid functioning have been chosen so far. First, the selective blockade or inverse agonism of the type 1… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 100 REFERENCES
    Cannabinoids and schizophrenia
    • 2
    Anandamide dysfunction in prodromal and established psychosis.
    • 20
    Cannabis and psychiatric disorders: it is not only addiction
    • 173
    Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia
    • 61
    Molecular characterization of a peripheral receptor for cannabinoids
    • 4,129
    • Highly Influential
    Pharmacological and molecular targets in the search for novel antipsychotics
    • 41
    Cannabidiol monotherapy for treatment-resistant schizophrenia
    • 139
    Cannabis-Associated Psychosis
    • 40
    A second endogenous cannabinoid that modulates long-term potentiation
    • 1,333